It also forms part of the criteria for the revised WHO classification for high-grade B cell lymphomas, defined as those with mutations in MYC in concert with either BCL6 or BCL2, which show poor responses to standard therapy [88]. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.